Results 201 to 210 of about 4,346,534 (345)
This graphical abstract illustrates the research workflow of natural polysaccharides, covering extraction approaches, deproteinization, depigmentation and purification procedures. Subsequent analyses include structural characterization, biological activity evaluation and structure‑activity relationship exploration to underpin polysaccharide research ...
Yian Zhao +7 more
wiley +1 more source
ABSTRACT Diffuse sclerosing osteomyelitis (DSO) of the mandible is a chronic nonbacterial inflammatory bone disease. We report a 65‐year‐old woman with ulcerative colitis who presented with swelling and pain of the left mandible. The lesion was refractory to tooth extraction, prolonged antibiotics, and nonsteroidal anti‐inflammatory drugs.
Mayumi Yao +5 more
wiley +1 more source
Differential intrahepatic integrated HBV DNA patterns between HBeAg-positive and HBeAg-negative chronic hepatitis B. [PDF]
Lau DT +14 more
europepmc +1 more source
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie +4 more
wiley +1 more source
Comment on "A single-cell digital PCR method tailored for quantification of HBV DNA positive cells in liver biopsy tissues". [PDF]
Chen Y, Zhao G, Song J.
europepmc +1 more source
ABSTRACT Background and Aims Sri Lanka lacks nationwide data on the incidence and characteristics of hepatocellular carcinoma (HCC); there is no prospective national HCC registry, and the only published clinical series comes from a single tertiary centre.
Madunil Anuk Niriella +29 more
wiley +1 more source
HBsAg seroclearance with HBV DNA <100 IU/mL and long-term risks of adverse liver events, all-cause mortality, and cause-specific mortality in chronic hepatitis B: a prospective cohort study. [PDF]
Zhang Y +15 more
europepmc +1 more source
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus +7 more
wiley +1 more source
The Role of Integrated HBV DNA in the Quest for a Cure in HIV/HBV co-infection. [PDF]
Mani M, Thio CL, Balagopal A.
europepmc +1 more source
Journal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
Erwan Vo‐Quang +6 more
wiley +1 more source

